|
Different groups
|
P-tau
|
VILIP-1
|
YKL-40
|
Difference P-tau vs VILIP-1
|
Difference P-tau vs YKL-40
|
Difference VILIP-1 vs YKL-40
|
|---|
|
Associations between neurodegeneration biomarkers and Aβ pathology within diagnostic group
|
|
CN Aβ− vs CN Aβ+
|
0.500 (0.033)
|
0.372 (0.168)
|
0.582 (0.144)
|
0.128 (0.713)
|
−0.083 (0.855)
|
−0.211 (0.657)
|
|
sMCI Aβ− vs sMCI Aβ+
|
0.854 (0.014)
|
− 0.014 (0.970)
|
0.210 (0.634)
|
0.869 (0.092)
|
0.645 (0.246)
|
−0.224 (0.699)
|
|
pMCI Aβ− vs pMCI Aβ+
|
1.130 (0.002)
|
0.619 (0.017)
|
0.466(0.291)
|
0.516 (0.371)
|
0.669 (0.243)
|
0.153 (0.809)
|
|
Associations between neurodegeneration biomarkers and combinations of clinical diagnosis and Aβ pathology
|
|
CN Aβ− vs CN Aβ+
|
0.500 (0.033)
|
0.372 (0.168)
|
0.582(0.144)
|
0.128 (0.713)
|
−0.083 (0.855)
|
−0.211 (0.657)
|
|
CN Aβ− vs sMCI Aβ+
|
0.716 (0.003)
|
0.274 (0.236)
|
0.055 (0.875)
|
0.442 (0.181)
|
0.661 (0.124)
|
0.219(0.603)
|
|
CN Aβ− vs pMCI Aβ+
|
1.120 (< 0.001)
|
0.941 (< 0.001)
|
0.344 (0.191)
|
0.176 (0.590)
|
0.773 (0.032)
|
0.597 (0.107)
|
|
CN Aβ− vs AD Aβ+
|
1.100 (< 0.001)
|
0.789 (0.007)
|
0.668 (0.038)
|
0.313 (0.378)
|
0.435 (0.262)
|
0.121 (0.773)
|
|
CN Aβ− vs sMCI Aβ−
|
−0.234 (0.261)
|
0.244 (0.439)
|
−0.198 (0.595)
|
− 0.477 (0.214)
|
−0.036 (0.934)
|
0.441 (0.370)
|
|
CN Aβ− vs pMCI Aβ−
|
−0.130 (0.560)
|
− 0.018 (0.959)
|
−0.264 (0.583)
|
− 0.112 (0.785)
|
0.134 (0.800)
|
0.246 (0.678)
|
- In different combinations of clinical diagnosis and Aβ pathology, data are are estimates from linear mixed-effects models evaluating effects of Aβ within diagnostic groups (top 3 rows), and differences between Aβ− CN and other combinations of diagnosis and Aβ pathology (bottom 6 rows). Results are β-coefficient (P-value). Bold values indicate significant associations
- Abbreviations: VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1, CN cognitively normal, sMCI stable mild cognitive impairment, pMCI progressive mild cognitive impairment, AD Alzheimer’s disease
